Staying Engaged During a Pandemic
Thomas Dilworth, PharmD, shares tips and resources that can help busy clinicians stay engaged and up to date during the COVID-19 pandemic.
Watch
Is Remdesivir a Viable Option for Treating COVID-19?
Matthew Davis, PharmD, provides an overview on the agent remdesivir.
COVID-19: ACEIs, ARBS, and NSAIDs
Thomas Dilworth, PharmD, provides a recap of ACEIs, ARBs, and NSAIDs in patients with COVID-19.
Did SARS-CoV-2 Originate in Animal Markets?
Jason Kindrachuk, PhD, explains the animal reservoir spillover events involved in the emergence of viruses like SARS-CoV-2.
Assessing Kaletra for COVID-19
Krutika N. Mediwala, PharmD, BCPS, BCIDP, provides a recap of available information regarding Kaletra for the treatment of COVID-19.
Jason Kindrachuk, PhD: Viral Shedding, Co-infection, and the Origins of SARS-CoV-2
Jason Kindrachuk, PhD, addresses clinician questions about SARS-CoV-2 such as the length of infectious viral shedding and whether the virus will become endemic.
Public Health Perspective: COVID-19 Lessons and Challenges
Wendy M. Bamberg, MD, the editor of Contagion®’s Emerging and Re-emerging Infections section, shares her thoughts on social distancing, managing suspect cases, and lessons we can learn about COVID-19.
Jason Kindrachuk, PhD: Understanding SARS-CoV-2 in an Emerging Virus Context
Jason Kindrachuk, PhD, situates the virus which causes COVID-19 in the context of past coronavirus outbreaks. This is part 1 of a 3-part interview.
Concepts of HIV Cure Explained
Ian Frank, MD, explains the different conceptual understandings of what an HIV cure might entail.
The Thai Trial and Other HIV Vaccine Studies
Ian Frank, MD, gives an overview of different HIV vaccine efforts in recent years and on the horizon.
Evaluating Therapies for COVID-19 and Staying Engaged During a Pandemic
Erin K. McCreary, PharmD, BCPS, BCIDP, discusses emerging literature on potential therapies COVID-19 and how the infectious disease community can work together during this pandemic.
Long-Acting ART, Islatravir, and Capsid Inhibitors
Ian Frank, MD, discusses upcoming treatments for people with HIV.
The Rise of Vaccine Misinformation
Tina Q. Tan, MD, discusses vaccine misinformation.
Why Flu Season Has Been Severe
Tina Q. Tan, MD, discusses the particular severity of the ongoing flu season.
How Does Hydroxychloroquine and Azithromycin Combination Therapy Measure Up For COVID-19 Treatment?
Jason Pogue, PharmD, BCPS, BCIDP, shares his thoughts on a study published in the International Journal of Antimicrobial Agents.
From the Frontlines: Insight Into Infection Prevention During COVID-19 Pandemic
Saskia v. Popescu, PhD, MPH, MA, CIC, a senior infection prevention epidemiologist in Phoenix, Arizona, discusses what it’s like for these frontline fighters and what we can do to “flatten the curve.”
The HIV Prevention Horizon
Colleen Kelley, MD, MPH, describes what's on the horizon in HIV prevention.
What "Ending the HIV Epidemic" Entails
Ian Frank, MD, explains the "Ending the Epidemic" initiative.
The HIV Vaccine Landscape
Colleen Kelley, MD, MPH, describes the current state of HIV vaccine efforts.
The Importance of Youth HIV Prevention
Colleen Kelley, MD, MPH, discusses the importance of targeted youth HIV prevention measures.
Recent Themes in HIV Science
Colleen Kelley, MD, MPH, associate professor at the Emory University School of Medicine, discusses some of the ongoing themes in developing HIV science.
Including Women in HIV Research
Ian Frank, MD, discusses the need to include women in HIV research.
Barriers to PrEP Implementation
Colleen Kelley, MD, MPH, describes barriers to the implementation of HIV pre-exposure prophylaxis.
Coronavirus in a Global Society
Ian Frank, MD, discusses the global character of the novel coronavirus.
Potential Complications from Flu
Jason Gallagher, PharmD, discusses the risk factors for experiencing complications of influenza.
Community Outreach for Dental Antibiotic Stewardship
Debra Goff, PharmD, describes the success of a community outreach approach to spreading the word about antimicrobial stewardship among dentists and orthopedic surgeons.
Notable Drug Approvals of 2019
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, discusses the significant drug approvals in ID over the course of 2019.
Reflecting on HIV Diagnosis
Jason Tokumoto, MD, reflects on the ways people respond to HIV diagnosis.
Drivers of Costs in ID Treatment
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, explains some of the factors which underlie the cost of ID treatment.
Contemporary Challenges in ID Treatment
Jason Gallagher, PharmD, FCCP, FIDSA, BCPS, explains contemporary challenges facing ID clinicians individually and as a profession.